Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the two organizations announced that Kyoto University was transferring the first novel induced pluripotent stem (iPS) cell-derived chimeric antigen receptor (CAR-T) therapy to Takeda.